{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:59:08Z","timestamp":1793498348445,"version":"4.5.0"},"reference-count":169,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"15","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2023,12,27]]},"DOI":"10.1167\/iovs.64.15.36","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T10:31:02Z","timestamp":1703673062000},"page":"36","source":"Crossref","is-referenced-by-count":31,"title":["PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma"],"prefix":"10.1167","volume":"64","author":[{"given":"Maria Chiara","family":"Gelmi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul\u00e7in","family":"Gezgin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"van der Velden","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorius P. M.","family":"Luyten","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sietse J.","family":"Luk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam H. M.","family":"Heemskerk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0161-6420(03)00077-0","article-title":"Survival rates with uveal melanoma in the United States: 1973\u20131997","volume":"110","author":"Singh","year":"2003","journal-title":"Ophthalmology"},{"key":"bib3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ajo.2004.07.006","article-title":"The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24","volume":"138","author":"Hawkins","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","article-title":"Effectiveness of treatments for metastatic uveal melanoma","volume":"148","author":"Augsburger","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"key":"bib6","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative Ocular Melanoma Study Group Report No. 26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Opthalmol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/archopht.126.10.1413","article-title":"Survival in patients with uveal melanoma in Europe","volume":"126","author":"Virgili","year":"2008","journal-title":"Arch Opthalmol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000509918","article-title":"Five decades of enucleations for uveal melanoma in one center: more tumors with high risk factors, no improvement in survival over time","volume":"7","author":"Roelofsen","year":"2021","journal-title":"Ocul Oncol Pathol"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2016.34.15_suppl.3016","article-title":"Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma","volume":"34","author":"Middleton","year":"2016","journal-title":"J Clinic Oncol"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"S1442","DOI":"10.1016\/j.annonc.2020.10.552","article-title":"64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)","volume":"31","author":"Sacco","year":"2020","journal-title":"Ann Oncol"},{"key":"bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1702","article-title":"1757O Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients","volume":"32","author":"Shoushtari","year":"2021","journal-title":"Ann Oncol"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.v67.2","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"bib16","first-page":"186","article-title":"Uveal melanoma treatment and prognostication","volume":"6","author":"Dogrus\u00f6z","year":"2017","journal-title":"Asia Pac J Ophthalmol"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/aos.2018.96.issue-4","article-title":"Genetic prognostication in uveal melanoma","volume":"96","author":"Dogrus\u00f6z","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0165-4608(90)90090-W","article-title":"Monosomy 3 and isochromosome 8q in a uveal melanoma","volume":"45","author":"Horsman","year":"1990","journal-title":"Cancer Genet Cytogenet"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1167\/iovs.06-0101","article-title":"Clinical and cytogenetic analyses in uveal melanoma","volume":"47","author":"Kilic","year":"2006","journal-title":"Invest Opthalmol Vis Sci"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-10-2076","article-title":"Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification","volume":"16","author":"Damato","year":"2010","journal-title":"Clin Cancer Res"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1167\/iovs.13-12195","article-title":"Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome","volume":"54","author":"Ewens","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma","volume":"83","author":"White","year":"1998","journal-title":"Cancer"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1167\/iovs.08-3165","article-title":"Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death","volume":"50","author":"Damato","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.ophtha.2018.03.011","article-title":"The Cancer Genome Atlas Project: an integrated molecular view of uveal melanoma","volume":"125","author":"Jager","year":"2018","journal-title":"Ophthalmology"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","article-title":"Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death","volume":"64","author":"Onken","year":"2004","journal-title":"Cancer Res"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat Genet"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","journal-title":"Ophthalmology"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","article-title":"SF3B1 mutations are associated with alternative splicing in uveal melanoma","volume":"3","author":"Furney","year":"2013","journal-title":"Cancer Discov"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1167\/iovs.14-14550","article-title":"Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma","volume":"55","author":"Ewens","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1186\/s12885-018-5079-x","article-title":"Comparison of germline versus somatic BAP1 mutations for risk of metastasis in uveal melanoma","volume":"18","author":"Ewens","year":"2018","journal-title":"BMC Cancer"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/sj.bjc.6601374","article-title":"Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development","volume":"89","author":"Zuidervaart","year":"2003","journal-title":"Br J Cancer"},{"key":"bib34","first-page":"2578","article-title":"Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities","volume":"63","author":"Tschentscher","year":"2003","journal-title":"Cancer Res"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1167\/iovs.08-2033","article-title":"Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis","volume":"49","author":"van Gils","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1158\/1078-0432.CCR-06-2401","article-title":"Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma","volume":"13","author":"Worley","year":"2007","journal-title":"Clin Cancer Res"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2353\/jmoldx.2010.090220","article-title":"An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma","volume":"12","author":"Onken","year":"2010","journal-title":"J Mol Diagn"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-1-62703-727-3","article-title":"A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile","volume":"1102","author":"Harbour","year":"2014","journal-title":"Methods Mol Biol"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/ICU.0000000000000051","article-title":"Recent developments in prognostic and predictive testing in uveal melanoma","volume":"25","author":"Field","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13000-017-0650-3","article-title":"Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics","volume":"12","author":"Plasseraud","year":"2017","journal-title":"Diagn Pathol"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"37824","DOI":"10.18632\/oncotarget.v6i35","article-title":"Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma","volume":"6","author":"de Lange","year":"2015","journal-title":"Oncotarget"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-07-5144","article-title":"A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis","volume":"14","author":"Onken","year":"2008","journal-title":"Clin Cancer Res"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1167\/iovs.16-20212","article-title":"The prognostic value of AJCC staging in uveal melanoma is enhanced by adding chromosome 3 and 8q status","volume":"58","author":"Dogrus\u00f6z","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41433-021-01710-y","article-title":"Survival analysis following enucleation for uveal melanoma","volume":"36","author":"Negretti","year":"2021","journal-title":"Eye (Lond)"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1504\/IJBET.2012.045355","article-title":"Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis","volume":"8","author":"Eleuteri","year":"2012","journal-title":"Int J Biomed Eng Technol"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.compbiomed.2018.09.024","article-title":"Prognostication of metastatic death in uveal melanoma patients: a Markov multi-state model","volume":"102","author":"Eleuteri","year":"2018","journal-title":"Comput Biol Med"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"100297","DOI":"10.1016\/j.xops.2023.100297","article-title":"Increased histological tumor pigmentation in uveal melanoma is related to eye color and loss of chromosome 3\/BAP1","volume":"3","author":"Gelmi","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ophtha.2021.11.018","article-title":"Adding the cancer genome atlas chromosome classes to American Joint Committee on cancer system offers more precise prognostication in uveal melanoma","volume":"129","author":"Gelmi","year":"2022","journal-title":"Ophthalmology"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Invest"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/imt-2017-0066","article-title":"PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma","volume":"9","author":"Javed","year":"2017","journal-title":"Immunotherapy"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/ijms21030879","article-title":"The role of immune checkpoint blockade in uveal melanoma","volume":"21","author":"Wessely","year":"2020","journal-title":"Int J Mol Sci"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/IIO.0000000000000263","article-title":"Immune checkpoint inhibitors in uveal and conjunctival melanoma","volume":"59","author":"Wierenga","year":"2019","journal-title":"Int Ophthalmol Clin"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/0284186X.2016.1260773","article-title":"Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands","volume":"56","author":"van der Kooij","year":"2017","journal-title":"Acta Oncol"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s41467-018-04322-5","article-title":"Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors","volume":"9","author":"Rodrigues","year":"2018","journal-title":"Nat Commun"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00251-019-01108-x","article-title":"Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab","volume":"71","author":"Johansson","year":"2019","journal-title":"Immunogenetics"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejca.2022.06.033","article-title":"MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients","volume":"173","author":"Saint-Ghislain","year":"2022","journal-title":"Eur J Cancer"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00008390-199802000-00003","article-title":"Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines","volume":"8","author":"Luyten","year":"1998","journal-title":"Melanoma Res"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/A:1018479011340","article-title":"Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease","volume":"15","author":"Chen","year":"1996","journal-title":"Clin Exp Metastasis"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Infrequent expression of the MAGE gene family in uveal melanomas","volume":"66","author":"Mulcahy","year":"1996","journal-title":"Int J Cancer"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/bjophthalmol-2011-300432","article-title":"Expression of cancer-testis antigens (MAGE-A1, MAGE-A3\/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma","volume":"96","author":"Errington","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib69","doi-asserted-by":"publisher","first-page":"59209","DOI":"10.18632\/oncotarget.v7i37","article-title":"Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas","volume":"7","author":"Field","year":"2016","journal-title":"Oncotarget"},{"key":"bib70","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"PRAME as a potential target for immunotherapy in metastatic uveal melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"bib71","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"bib72","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","author":"Amir","year":"2011","journal-title":"Clin Cancer Res"},{"key":"bib73","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"bib74","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol"},{"key":"bib75","doi-asserted-by":"crossref","first-page":"8828579","DOI":"10.1155\/2020\/8828579","article-title":"Clinicopathological and prognostic significance of PRAME overexpression in human cancer: a meta-analysis","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res Int"},{"key":"bib76","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1046\/j.1365-2141.1998.00982.x","article-title":"PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells","volume":"102","author":"Van Baren","year":"1998","journal-title":"Br J Haematol"},{"key":"bib77","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0165-4608(01)00570-2","article-title":"Clinical implications of PRAME gene expression in childhood acute myeloid leukemia","volume":"133","author":"Steinbach","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"bib78","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12185-014-1593-z","article-title":"Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy","volume":"100","author":"Mitsuhashi","year":"2014","journal-title":"Int J Hematol"},{"key":"bib79","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000381533","article-title":"PRAME expression and its clinical relevance in Hodgkin's lymphoma","volume":"134","author":"Ercolak","year":"2015","journal-title":"Acta Haematol"},{"key":"bib80","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/bloodadvances.2019000564","article-title":"Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia","volume":"3","author":"Huang","year":"2019","journal-title":"Blood Adv"},{"key":"bib81","doi-asserted-by":"publisher","first-page":"e145343","DOI":"10.1172\/JCI145343","article-title":"Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma","volume":"132","author":"Takata","year":"2022","journal-title":"J Clin Invest"},{"key":"bib82","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1046\/j.1365-2141.2001.02670.x","article-title":"Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia","volume":"112","author":"Matsushita","year":"2001","journal-title":"Br J Haematol"},{"key":"bib83","doi-asserted-by":"publisher","first-page":"e58052","DOI":"10.1371\/journal.pone.0058052","article-title":"PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs","volume":"8","author":"Wadelin","year":"2013","journal-title":"PLoS One"},{"key":"bib84","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1158\/0008-5472.CAN-04-4011","article-title":"Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo","volume":"65","author":"Tajeddine","year":"2005","journal-title":"Cancer Res"},{"key":"bib85","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"bib86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cancergencyto.2007.05.011","article-title":"PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia","volume":"177","author":"Steinbach","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"bib87","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1038\/emboj.2011.262","article-title":"The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters","volume":"30","author":"Costessi","year":"2011","journal-title":"EMBO J"},{"key":"bib88","doi-asserted-by":"publisher","first-page":"e42822","DOI":"10.1371\/journal.pone.0042822","article-title":"The human EKC\/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME","volume":"7","author":"Costessi","year":"2012","journal-title":"PLoS One"},{"key":"bib89","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-018-1757-3","article-title":"PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer","volume":"17","author":"Al-Khadairi","year":"2019","journal-title":"J Transl Med"},{"key":"bib90","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-023-02887-0","article-title":"PRAME induces genomic instability in uveal melanoma.","author":"Kurtenbach","year":"2023","journal-title":"Oncogene"},{"key":"bib91","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00417-019-04335-w","article-title":"Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma","volume":"257","author":"Schefler","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib92","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s13577-022-00808-z","article-title":"Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients","volume":"36","author":"Kumar","year":"2023","journal-title":"Hum Cell"},{"key":"bib93","first-page":"2870","article-title":"Design, methods, and rationale for the Collaborative Ocular Oncology Group 2 (COOG2) study","volume":"62","author":"Schefler","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib94","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1097\/PAS.0000000000000645","article-title":"Comparing the prognostic value of BAP1 mutation pattern, chromosome 3 status, and BAP1 immunohistochemistry in uveal melanoma","volume":"40","author":"van de Nes","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"bib95","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/modpathol.2014.43","article-title":"Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma","volume":"27","author":"Koopmans","year":"2014","journal-title":"Mod Pathol"},{"key":"bib96","doi-asserted-by":"publisher","first-page":"e0116371","DOI":"10.1371\/journal.pone.0116371","article-title":"Digital PCR validates 8q dosage as prognostic tool in uveal melanoma","volume":"10","author":"Versluis","year":"2015","journal-title":"PLoS One"},{"key":"bib97","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00262-017-1991-1","article-title":"Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment","volume":"66","author":"Gezgin","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"bib98","doi-asserted-by":"publisher","first-page":"e0164292","DOI":"10.1371\/journal.pone.0164292","article-title":"Upregulation of HLA expression in primary uveal melanoma by infiltrating leukocytes","volume":"11","author":"van Essen","year":"2016","journal-title":"PLoS One"},{"key":"bib99","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1167\/iovs.07-0786","article-title":"Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma","volume":"49","author":"Maat","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib100","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1159\/000334576","article-title":"Uveal melanoma: the inflammatory microenvironment","volume":"4","author":"Bronkhorst","year":"2012","journal-title":"J Innate Immun"},{"key":"bib101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09273949609069122","article-title":"Differential expression of HLA-A and B-alleles on uveal melanoma as determined by immuno-histology","volume":"4","author":"de Waard-Siebinga","year":"1996","journal-title":"Ocul Immunol Inflamm"},{"key":"bib102","first-page":"1865","article-title":"Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma","volume":"38","author":"Blom","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib103","first-page":"2153","article-title":"Association of HLA class I and class II antigen expression and mortality in uveal melanoma","volume":"42","author":"Ericsson","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib104","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0198-8859(02)00389-0","article-title":"HLA expression in uveal melanoma: there is no rule without some exception","volume":"63","author":"Jager","year":"2002","journal-title":"Human Immunol"},{"key":"bib105","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cmet.2020.06.002","article-title":"Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress","volume":"32","author":"Cheng","year":"2020","journal-title":"Cell Metab"},{"key":"bib106","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12885-021-07976-5","article-title":"Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer","volume":"21","author":"He","year":"2021","journal-title":"BMC Cancer"},{"key":"bib107","doi-asserted-by":"publisher","first-page":"110995","DOI":"10.1016\/j.celrep.2022.110995","article-title":"Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached","volume":"39","author":"Wilcock","year":"2022","journal-title":"Cell Rep"},{"key":"bib108","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1128\/MCB.00112-09","article-title":"The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors","volume":"29","author":"Watson","year":"2009","journal-title":"Mol Cell Biol"},{"key":"bib109","doi-asserted-by":"publisher","first-page":"22408","DOI":"10.1074\/jbc.M112.357301","article-title":"Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner","volume":"287","author":"Cerna","year":"2012","journal-title":"J Biol Chem"},{"key":"bib110","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.1158\/1078-0432.CCR-13-1186","article-title":"Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors","volume":"19","author":"Shames","year":"2013","journal-title":"Clin Cancer Res"},{"key":"bib111","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1515\/med-2022-0418","article-title":"SLCO4A1-AS1 mediates pancreatic cancer development via miR-4673\/KIF21B axis","volume":"17","author":"Zhang","year":"2022","journal-title":"Open Med (Wars)"},{"key":"bib112","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3389\/fimmu.2019.00819","article-title":"Emerging role of lymphocyte antigen-6 family of genes in cancer and immune cells","volume":"10","author":"Upadhyay","year":"2019","journal-title":"Front Immunol"},{"key":"bib113","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1158\/0008-5472.CAN-15-2654","article-title":"Ly6E\/K signaling to TGFbeta promotes breast cancer progression, immune escape, and drug resistance","volume":"76","author":"AlHossiny","year":"2016","journal-title":"Cancer Res"},{"key":"bib114","doi-asserted-by":"publisher","first-page":"65837","DOI":"10.18632\/oncotarget.v7i40","article-title":"LY6E: a conductor of malignant tumor growth through modulation of the PTEN\/PI3K\/Akt\/HIF-1 axis","volume":"7","author":"Yeom","year":"2016","journal-title":"Oncotarget"},{"key":"bib115","doi-asserted-by":"publisher","first-page":"8908","DOI":"10.1093\/nar\/gky658","article-title":"PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress","volume":"46","author":"Schleicher","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"bib116","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/cancers11060751","article-title":"PARP inhibition increases the response to chemotherapy in uveal melanoma","volume":"11","author":"de Koning","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib117","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/0008-5472.CAN-10-0605","article-title":"High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients","volume":"71","author":"Laurent","year":"2011","journal-title":"Cancer Res"},{"key":"bib118","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1167\/iovs.15-18780","article-title":"Protein tyrosine phosphatase 4A3 (PTP4A3) promotes human uveal melanoma aggressiveness through membrane accumulation of matrix metalloproteinase 14 (MMP14)","volume":"57","author":"Maacha","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib119","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1038\/s41598-019-39643-y","article-title":"Protein tyrosine phosphatase 4A3 (PTP4A3\/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2","volume":"9","author":"Duciel","year":"2019","journal-title":"Sci Rep"},{"key":"bib120","doi-asserted-by":"publisher","first-page":"1111522","DOI":"10.3389\/fonc.2023.1111522","article-title":"Emerging functions of C\/EBPbeta in breast cancer","volume":"13","author":"Matherne","year":"2023","journal-title":"Front Oncol"},{"key":"bib121","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/mc.v58.5","article-title":"Emerging role of EPHX1 in chemoresistance of acute myeloid leukemia by regulating drug-metabolizing enzymes and apoptotic signaling","volume":"58","author":"Cheng","year":"2019","journal-title":"Mol Carcinog"},{"key":"bib122","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.2147\/OTT.S294332","article-title":"DNASE1L3 as a prognostic biomarker associated with immune cell infiltration in cancer","volume":"14","author":"Deng","year":"2021","journal-title":"Onco Targets Ther"},{"key":"bib123","doi-asserted-by":"publisher","first-page":"e43721","DOI":"10.1371\/journal.pone.0043721","article-title":"Suppression of cancer progression by MGAT1 shRNA knockdown","volume":"7","author":"Beheshti Zavareh","year":"2012","journal-title":"PLoS One"},{"key":"bib124","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12885-017-3960-7","article-title":"MGAT1 is a novel transcriptional target of Wnt\/beta-catenin signaling pathway","volume":"18","author":"Akiva","year":"2018","journal-title":"BMC Cancer"},{"key":"bib125","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.2147\/CMAR","article-title":"Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer","volume":"11","author":"Ren","year":"2019","journal-title":"Cancer Manag Res"},{"key":"bib126","doi-asserted-by":"publisher","first-page":"380","DOI":"10.21037\/atm","article-title":"Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer","volume":"7","author":"Yi","year":"2019","journal-title":"Ann Transl Med"},{"key":"bib127","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3389\/fonc.2020.01436","article-title":"Apolipoprotein C1 (APOC1): a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma","volume":"10","author":"Cui","year":"2020","journal-title":"Front Oncol"},{"key":"bib128","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/aji.1998.40.issue-3","article-title":"Major histocompatibility complex expression on human, malegerm cells: a review","volume":"40","author":"Fiszer","year":"1998","journal-title":"Am J Reprod Immunol"},{"key":"bib129","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/cmi.2014.38","article-title":"Testicular defense systems: immune privilege and innate immunity","volume":"11","author":"Zhao","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"bib130","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1084\/jem.193.1.73","article-title":"Efficient identification of novel HLA-A * 0201\u2013presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis","volume":"193","author":"Kessler","year":"2001","journal-title":"J Exp Med"},{"key":"bib131","doi-asserted-by":"publisher","first-page":"1121973","DOI":"10.3389\/fimmu.2023.1121973","article-title":"PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer","volume":"14","author":"van Amerongen","year":"2023","journal-title":"Front Immunol"},{"key":"bib132","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/CJI.0000000000000095","article-title":"A comprehensive preclinical model evaluating the recombinant PRAME antigen combined with the AS15 immunostimulant to fight against PRAME-expressing tumors","volume":"38","author":"G\u00e9rard","year":"2015","journal-title":"J Immunother"},{"key":"bib133","doi-asserted-by":"publisher","first-page":"e000068","DOI":"10.1136\/esmoopen-2016-000068","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study","volume":"1","author":"Gutzmer","year":"2016","journal-title":"ESMO Open"},{"key":"bib134","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study","volume":"11","author":"Pujol","year":"2016","journal-title":"J Thorac Oncol"},{"key":"bib135","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/CJI.0b013e3182280db1","article-title":"A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors","volume":"34","author":"Weber","year":"2011","journal-title":"J Immunother"},{"key":"bib136","first-page":"855","article-title":"Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts","volume":"28","author":"Li","year":"2006","journal-title":"Int J Oncol"},{"key":"bib137","doi-asserted-by":"publisher","first-page":"e1117","DOI":"10.1002\/cti2.v9.3","article-title":"Toll-like receptor 7\/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial","volume":"9","author":"Lichtenegger","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"bib139","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-05-2578","article-title":"Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy","volume":"12","author":"Griffioen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"bib140","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1182\/blood-2010-08-300376","article-title":"High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells","volume":"117","author":"Quintarelli","year":"2011","journal-title":"Blood"},{"key":"bib141","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2021.39.15_suppl.2538","article-title":"Preliminary analysis of a phase 1\/2 study of NEXI-001 donor-derived multi-antigen-specific CD8+ T-cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT)","volume":"39","author":"Al Malki","year":"2021","journal-title":"J Clinic Oncol"},{"key":"bib142","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-Cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib143","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1200\/JCO.2020.38.15_suppl.4622","article-title":"A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS)","volume":"38","author":"Smaglo","year":"2020","journal-title":"J Clinic Oncol"},{"key":"bib144","doi-asserted-by":"publisher","first-page":"17588359221107113","DOI":"10.1177\/17588359221107113","article-title":"Multi-antigen-targeted T-cell therapy to treat patients with relapsed\/refractory breast cancer","volume":"14","author":"Hoyos","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"bib145","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood"},{"key":"bib146","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/bloodadvances.2021006831","article-title":"Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT","volume":"6","author":"Kinoshita","year":"2022","journal-title":"Blood Adv"},{"key":"bib147","doi-asserted-by":"publisher","first-page":"iii306","DOI":"10.1093\/neuonc\/noaa222.137","article-title":"EPCT-15. The remind trial: multi-antigen targeted t cells for pediatric CNS tumors","volume":"22","author":"Grant","year":"2020","journal-title":"Neuro Oncol"},{"key":"bib148","doi-asserted-by":"publisher","first-page":"e32165","DOI":"10.1371\/journal.pone.0032165","article-title":"NYESO-1\/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine","volume":"7","author":"Pollack","year":"2012","journal-title":"PLoS One"},{"key":"bib149","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00262-011-1024-4","article-title":"Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine","volume":"60","author":"Yan","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"bib150","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1868-7083-5-3","article-title":"Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy","volume":"5","author":"Karahoca","year":"2013","journal-title":"Clin Epigenetics"},{"key":"bib151","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1158\/0008-5472.CAN-17-3140","article-title":"Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma","volume":"78","author":"Orlando","year":"2018","journal-title":"Cancer Res"},{"key":"bib152","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/cancers14081998","article-title":"T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity","volume":"14","author":"Sailer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"bib156","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1172\/JCI92335","article-title":"A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide\/HLA-I antigens","volume":"127","author":"Chang","year":"2017","journal-title":"J Clin Invest"},{"key":"bib157","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/bloodadvances.2022008304","article-title":"Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia","volume":"7","author":"Kirkey","year":"2023","journal-title":"Blood Adv"},{"key":"bib158","first-page":"3817","article-title":"Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization","volume":"54","author":"Speicher","year":"1994","journal-title":"Cancer Res"},{"key":"bib159","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-18-3052","article-title":"Integrative copy number analysis of uveal melanoma reveals novel candidate genes involved in tumorigenesis including a tumor suppressor role for PHF10\/BAF45a","volume":"25","author":"Anbunathan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"bib160","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/BF00165947","article-title":"C-myc oncogene expression in ocular melanomas","volume":"230","author":"Royds","year":"1992","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib161","first-page":"1097","article-title":"Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma","volume":"147","author":"Mooy","year":"1995","journal-title":"Am J Pathol"},{"key":"bib162","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00008390-199804000-00006","article-title":"The prognostic significance of c-myc oncogene expression in uveal melanoma","volume":"8","author":"Chana","year":"1998","journal-title":"Melanoma Res"},{"key":"bib163","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/bjo.83.1.110","article-title":"c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma","volume":"83","author":"Chana","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"bib164","first-page":"1679","article-title":"Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization","volume":"42","author":"Parrella","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib165","doi-asserted-by":"publisher","first-page":"19235","DOI":"10.1038\/s41598-019-55513-z","article-title":"Multi-platform omics analysis for identification of molecular characteristics and therapeutic targets of uveal melanoma","volume":"9","author":"Kim","year":"2019","journal-title":"Sci Rep"},{"key":"bib166","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1158\/1078-0432.CCR-04-1941","article-title":"DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma","volume":"11","author":"Ehlers","year":"2005","journal-title":"Clin Cancer Res"},{"key":"bib167","doi-asserted-by":"publisher","first-page":"R1186","DOI":"10.1186\/bcr1356","article-title":"High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization","volume":"7","author":"Naylor","year":"2005","journal-title":"Breast Cancer Res"},{"key":"bib168","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1053\/jhep.2003.50457","article-title":"PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas","volume":"38","author":"Okamoto","year":"2003","journal-title":"Hepatology"},{"key":"bib169","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1167\/iovs.11-8901","article-title":"A comparison of HLA genotype with inflammation in uveal melanoma","volume":"53","author":"van Essen","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib138","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129749","article-title":"DC vaccination induces antigen specific immune responses in AML patients: a 1-year interim assessment","author":"Eckl","year":"2019"},{"key":"bib153","article-title":"Medigene presents final phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers","author":"Medigene","year":"2023"},{"key":"bib154","article-title":"Immatics reports interim clinical data from ongoing phase 1b cohort a monotherapy with ACTengine IMA203 TCR-T targeting PRAME","author":"Immatics","year":"2023"},{"key":"bib155","article-title":"Phase 1 dose escalation of IMC-F106C, the first PRAME \u00d7 CD3 ImmTAC bispecific protein in solid tumors.","author":"Immunocore","year":"2022"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2793223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:43Z","timestamp":1791927103000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2793223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":169,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.64.15.36","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}